SlideShare a Scribd company logo
1 of 33
As Per PCI Regulations /B. Parm. VI
Sem./Pharmaceutical Quality
Assurance
UNIT-1
ICH Guideline
Presented By: VIVEK JAIN
M.Pharm. (Pharmaceutical Analysis)
Associate Professor
ADINA Institute Of Pharmaceutical
Sciences, Sagar (M.P.)
EMAIL:pharmamakers2010@gmail.com
ICH (April 1990)
• International Conference on Harmonisation (ICH) was created in
april 1990
• The European Medicines Agency publishes scientific guidelines
that are harmonised between Europe, Japan and the United
States of America
• ICH guidelines are provided for: Quality. Safety and Efficacy of
medicines.
MISSION
Harmonisation for Better Health
To make recommendations towards achieving
greater harmonisation in the interpretation and
application of technical guidelines and requirements
for pharmaceutical product registration and the
maintenance of such registrations
PURPOSE
 To Harmonize of technical requirements for registration or
marketing approval
 To Ensure quality, safety, efficacy of medicines
 To prevent unnecessary duplication of clinical trials on
humans
 To Minimize the use of animal testing without compromising
safety and effectiveness
 To promote public health
history
Need to harmonize, Because of the following reasons:
1. Industry becoming global
2. Duplicate test procedures
 time consuming
 expensive
3. Increase R &D costs
4. Meeting public demand
• Initiation of ICH
• 1980s Formulate European community
• 1989s WHO conference on DRA, Paris
• 1990s birth of ICH (created by all three Japan, USA & Europe)
• Topic of harmonization divided into : safety, quality and
efficacy
ICH structure
region Regulatory body
Japan MHLW ( ministry of health, labour and
welfare)
Europe EU (European unions)
US FDA
ICH members
Process of Harmonisation
ICH harmonisation activities fall into 4 categories;
1.Formal ICH Procedure
2.Q&A Procedure
3.Revision Procedure
4,.Maintenance Procedure
BRIEF OVERVIEW OF QSEM WITH SPECIAL EMPHASIS ON Q-
SERIES GUIDELINES
The ICH topics are divided into four categories
•Q – QUALITY GUIDELINES
•S – SAFETY GUIDELINES
•E - EFFICACY GUIDELINES
•M - MULTIDISCIPLINARY GUIDELINES
•Carcinogenicity (carcinogen any
substance that produce cancer)
•Genotoxicity (genetic toxicity)
•Reprotoxicity toxicity related to
reproduction
•ICH medical terminology (MedDRA)
•Common Technical Document (CTD)
•The development of Electronic
Standards for the Transfer of Regulatory
Information (ESTRI).
Q – QUALITY GUIDELINES
Q 1 S Stability
Q 2 A Analytical validation
Q 3 I Impurities
Q 4 P Pharmacopoeias
Q 5 B Quality of Biotechnology Products
Q 6 S Specifications
Q 7 API Good Manufacturing Guide for Active Pharmaceutical Ingredients
Q 8 PD Pharmaceutical Development
Q 9 QRM Quality Risk Management
Q 10 PQS Pharmaceutical Quality System
Q 11 DMDS Development and Manufacture of Drug Substances (Chemical
Entities Biotechnological/Biological Entities)
Q 12 LCM Life Cycle Management
Q – QUALITY GUIDELINES
Q 1 A – Q 1 F Stability
• Q1A – Stability Testing of New Drug Substances and
Products
• Q1 B – Stability Testing : Photo Stability Testing of New Drug
Substances and Products
• Q1C – Stability Testing for New Dosage Forms
• Q1D – Bracketing and Matrixing Designs for Stability Testing
of New Drug Substances and Products
• Q1E – Evaluation of Stability Data
• Q1F – Stability Data Package for Registration Application in
Climatic Zones III and IV
Q2 (R1) – Validation of Analytical Procedures: Text and
Methodology
Q3A- Q3D Impurities
• Q3A - Impurities in New Drug Substances
• Q3B – Impurities in New Drug Products
• Q3C– Impurities : Guideline for Residual Solvents
• Q3D – Impurities : Guideline for Elemental Impurities
• Q4 – Pharmacopoeias
• Q4A – Pharmacopoeial Harmonisation
• Q4B – Evaluation and Recommendation of Pharmacopoeial Text for
use in the ICH Regions
•
• Q4B Annex 2(R1) – Test for Extractable Volume of Parenteral
Preparation General Chapter
• Q4B – Annex 3(R1) – Test for Particulate Contamination : Sub-
Visibal Particales General Chapter
• Q4B – Annex 4A(R1) – Microbiological Examination of Non-
Sterile Products : Microbial Enumeration Tests General
Chapter
• Q4B – Annex 4B(R1) – Microbiological Examination of Non-
Sterile Products : Test for Specified Micro-Organism General
Chapter
• Q4B – Annex 4C(R1) – Microbiological Examination of Non-
Sterile Products : Acceptance Criteria for Pharmaceutical
Preparations and Substances for Pharmaceutical use General
Chapter
• Q4B – Annex 5(R1) – Disintegration Test General Chapter
• Q4B Annex 6 (R1) – Uniformity of Dosage Units General
Chapter
• Q4B Annex 7(R2) – Dissolution Test General Chapter
• Q4B Annex 8(R1) – Stability Test General Chapter
• Q4B Annex 9(R1) – Tablet Friability General Chapter
• Q4B Annex 10(R1) – Polyacrylamide Gel Electrophoresis
General Chapter
• Q4B Annex 11 – Capillary Electrophoresis General Chapter
• Q4B Annex 12 – Analytical Sieving General Chapter
• Q4B Annex 13 – Bulk Density and Tapped Density of
Powders General Chapter
• Q4B Annex 14 – Bacterial Endotoxin Test General Chapter
Q5A-Q5E Quality of Biotechnology Products
• Q5A (R1) – Viral Safety Evaluation of Biotechnology Products
Derived from Cell Lines of Human or Animal Origin
• Q5B – Quality of Biotechnology Products :
• Q5C – Quality of Biotechnology Products :Quality of
Biotechnological
• Q5D – Derivation and Characterisation of Cell Substrates
used for Production of Biotechnological/Biological Products
• Q5E – Comparability of Biotechnological/Biological Products
Subject to Changes in their Manufacturing Process
• Q6A-Q6B Specifications
• Q6A – Specifications : Test Procedure and Acceptance
Criteria for New Drug Substances and New Drug Products:
Chemical Substances
• Q6B – Specifications : Test Procedure and Acceptance
Criteria for Biotechnological/Biological
• Q7 – Good Manufacturing Guide for Active
Pharmaceutical Ingredients
• Q8(R2) – Pharmaceutical Development
• Q9 – Quality Risk Management
• Q10 – Pharmaceutical Quality System
• Q11 – Development and Manufacture of Drug Substances
(Chemical Entities Biotechnological/Biological Entities)
• Q12 – Life Cycle Management
S – SAFETY GUIDELINES
• S1A - S1C Carcinogenicity Studies
• S2 Genotoxicity Studies
• S3A - S3B Toxicokinetics and Pharmacokinetics
• S4 Toxicity Testing
• S5 Reproductive Toxicology
• S6 Biotechnological Products.
• S7A - S7B Pharmacology Studies
• S8 Immunotoxicology Studies
• S9 Nonclinical evaluation for anticancer
pharmaceuticals
• S10 Photo safety evaluation
• S11 Nonclinical paediatric safety
E - EFFICACY GUIDELINES
• E1 Clinical Safety For Drugs Used In Long-Term Treatment.
• E2A - E2F Pharmacovigilance.
• E3 Clinical Study Reports.
• E4 Dose-Response Studies.
• E5 Ethnic Factors. Code.
• E6 Good Clinical Practice.
• E7 Clinical Trials In Geriatric Population.
• E8 General Considerations For Clinical Trials
• E9 Statistical Principles For Clinical Trials
• E10 Choice Of Control Group In Clinical Trials
• E11 Clinical Trials In Paediatric Population
• E12 Clinical Evaluation By Therapeutic Category
• E14 Clinical Evaluation Of QT
• E15 Definitions Of Pharmacogenetics
• E16 Qualification Of Genomic Biomarkers
• E17 Multiregional Clinical Trials
• E18 Genomic Sampling
• E19 Safety Data Collection
M - MULTIDISCIPLINARY GUIDELINES
• M1 MedDRA Terminology
• M2 Electronic Standards
• M3 Nonclinical Safety Studies
• M4 Common Technical Document
• M5 Data Elements and Standards for
Drug Dictionaries
• M6 Gene Therapy
• M7 Genotoxic Impurities
• M8 Electronic Common Technical
Document (eCTD)
• M9 Biopharmaceutics Classification
System-based Biowaivers
• M10 Bioanalytical Method Validation
Stability guideline
• General:
• Definition: Stability of pharmaceutical product may be
defined as the ability of pharmaceutical dosage form to
maintain the physical, chemical, microbiological and
therapeutics properties during the time of storage and
usage by the patient
• Purpose of stability testing is: To provide evidence on
how the quality of a drug substance or drug product varies
with time under the influence of a variety of
environmental factors such as temperature, humidity, and
light, and to establish a re-test period for the drug
substance or a shelf life for the drug product and
recommended storage conditions.
Stability protocol For Drug Substance
• General
• Stress testing
• Selection of batches
• Container and closure system
• Specifications
• Testing frequency
• Storage conditions
• Stability Commitment
• Evaluation
• Statements/Labeling
Stress Testing
• It is also known as force degradation study
• Stress testing of the drug substance can help identify
the likely degradation products, which can in turn
help establish the degradation pathways and the
intrinsic/natural stability of the molecule.
• Stress testing is likely to be carried out on a single
batch of the drug substance.
• It should include the effect of temperatures,
humidity (e.g., 75% RH or greater) where appropriate
oxidation, and photolysis on the drug substance.
Selection of Batches
• At least three primary batches of the drug substance
should be representative to quality of the material
used for production scale.
• Container Closure System
• The stability studies should be conducted on the drug
substance packaged in a container closure system that
is the same as the packaging proposed for storage and
distribution.
• Specification
• Specification, which is a list of tests, reference to
analytical procedures, and proposed acceptance
criteria, is addressed in ICH Q6A and Q6B.
Testing Frequency
frequency of testing should be sufficient to establish the
stability profile of the drug substance.
• For long-term studies, (For drug substances with a
proposed re-test period) at least 12 months, the
frequency of testing at the long term storage condition
should normally be every 3 months over the first year,
every 6 months over the second year, and annually
thereafter through the proposed re-test period.
• At the accelerated storage condition, a minimum of
three time points, including the initial and final time
points (e.g., 0, 3, and 6 months), from a 6-month study is
recommended.
• For intermediate studies: Min. 4 time points (0, 6, 9, 12
months) for a 12 months study
Storage Conditions General case
• .
•
Study
Long term*
Storage conditions
25°C ± 2°C
60% RH ± 5% RH
Minimum
time period
12
months
Intermediate
**
30°C ± 2°C/65% RH ± 5% RH 6 months
Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months
. Drug substances intended for storage in a
refrigerator
Long term 5°C ± 3°C 12 months
Accelerated 25°C±2°C 6 months
Drug substances intended for storage in a
freezer
Long term - 20°C ± 5°C 12 months
Stability Commitment
• In case where data submitted for registration do not cover
the proposed shelf life it is necessary to give commitment
to continue the stability studies post approval in order to
firmly establish the shelf life.
• Where the submission includes long term stability data
from three production batches covering the proposed shelf
life, a post approval commitment is considered
unnecessary.
Evaluation
• The purpose of the stability study is to establish re-test
period for DS and shelf life for drug product for future
batched based on evaluation of results obtained from
chemical, physical, biological, microbiological tests
• A systematic approach should be adopted in the
presentation and evaluation of the stability information,
which should include, as appropriate, results from the
physical, chemical, biological, and microbiological tests,
including particular attributes of the dosage form (for
example, dissolution rate for solid oral dosage forms).
Statements/Labeling
• A storage statement should be established for the labeling
in accordance with relevant national/regional
requirements.
• The statement should be based on the stability evaluation
of the drug product.
• There should be a direct link between the label storage
statement and the demonstrated stability of the drug
product.
• An expiration date should be displayed on the container
label.

More Related Content

What's hot

Glp 112070804004
Glp  112070804004Glp  112070804004
Glp 112070804004
Patel Parth
 
Complaint and recall handling
Complaint and recall handlingComplaint and recall handling
Complaint and recall handling
Dolly Gabriola
 

What's hot (20)

Ich guidelines
Ich guidelinesIch guidelines
Ich guidelines
 
PROCESS OF ICH (International Council for Harmonisation)
PROCESS OF ICH (International Council for Harmonisation)PROCESS OF ICH (International Council for Harmonisation)
PROCESS OF ICH (International Council for Harmonisation)
 
Out of specification (oos)1
Out of specification (oos)1Out of specification (oos)1
Out of specification (oos)1
 
Quality by design (qbd)
Quality by design (qbd)Quality by design (qbd)
Quality by design (qbd)
 
Document Maintenance in Pharmaceutical Industry
Document Maintenance in Pharmaceutical IndustryDocument Maintenance in Pharmaceutical Industry
Document Maintenance in Pharmaceutical Industry
 
Complaints (QUALITY ASSURANCE)
Complaints (QUALITY ASSURANCE)Complaints (QUALITY ASSURANCE)
Complaints (QUALITY ASSURANCE)
 
Ich guideline
Ich guidelineIch guideline
Ich guideline
 
Quality control on secondary packaging materials
Quality control on secondary packaging materialsQuality control on secondary packaging materials
Quality control on secondary packaging materials
 
ICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIESICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIES
 
Pharmaceutical Quality System .pdf
Pharmaceutical Quality System .pdfPharmaceutical Quality System .pdf
Pharmaceutical Quality System .pdf
 
Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)Pharmaceutical Quality by Design (QbD)
Pharmaceutical Quality by Design (QbD)
 
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLC
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLCQUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLC
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLC
 
Glp 112070804004
Glp  112070804004Glp  112070804004
Glp 112070804004
 
ICH Guidelines
ICH GuidelinesICH Guidelines
ICH Guidelines
 
Supac
Supac Supac
Supac
 
Complaint and recall handling
Complaint and recall handlingComplaint and recall handling
Complaint and recall handling
 
Complaints & Recalls
Complaints & RecallsComplaints & Recalls
Complaints & Recalls
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
ICH QSEM Guidelines
ICH QSEM GuidelinesICH QSEM Guidelines
ICH QSEM Guidelines
 
Pharmaceutical validation & it's types
 Pharmaceutical validation & it's types Pharmaceutical validation & it's types
Pharmaceutical validation & it's types
 

Similar to Ich Guidelines Au. Vivek Jain

Ich guidelines and protocols
Ich guidelines and protocolsIch guidelines and protocols
Ich guidelines and protocols
ceutics1315
 
Master of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH GiudelinesMaster of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH Giudelines
omkarmandlik678
 

Similar to Ich Guidelines Au. Vivek Jain (20)

special emphasis on Q series guidelines
special emphasis on Q series guidelines special emphasis on Q series guidelines
special emphasis on Q series guidelines
 
ICH guideline.pdf
ICH guideline.pdfICH guideline.pdf
ICH guideline.pdf
 
ICH Guidlines Overview.pptx
ICH Guidlines Overview.pptxICH Guidlines Overview.pptx
ICH Guidlines Overview.pptx
 
Ich guidelines and protocols
Ich guidelines and protocolsIch guidelines and protocols
Ich guidelines and protocols
 
Ich guidelines and protocols
Ich guidelines and protocolsIch guidelines and protocols
Ich guidelines and protocols
 
Pharmaceutical Guidelines
Pharmaceutical GuidelinesPharmaceutical Guidelines
Pharmaceutical Guidelines
 
Ich
IchIch
Ich
 
ICH.pptx
ICH.pptxICH.pptx
ICH.pptx
 
ICH GUIDELINES QSEM
ICH GUIDELINES QSEMICH GUIDELINES QSEM
ICH GUIDELINES QSEM
 
Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)Ich guidelines Q1A(R2)
Ich guidelines Q1A(R2)
 
Ich
IchIch
Ich
 
1.3 ICH .pdf
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdf
 
Master of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH GiudelinesMaster of pharmacy... Pharmaceutics ICH Giudelines
Master of pharmacy... Pharmaceutics ICH Giudelines
 
ICH- Objectives and stability guidelines
ICH- Objectives and stability guidelinesICH- Objectives and stability guidelines
ICH- Objectives and stability guidelines
 
overview of ich guidelines
overview of ich guidelines overview of ich guidelines
overview of ich guidelines
 
ichguidelines_Final.ppt
ichguidelines_Final.pptichguidelines_Final.ppt
ichguidelines_Final.ppt
 
Drug stability
Drug stability Drug stability
Drug stability
 
ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)
 
Ich guidlines M. Pharma (DRA IP )
Ich guidlines M. Pharma (DRA IP )Ich guidlines M. Pharma (DRA IP )
Ich guidlines M. Pharma (DRA IP )
 
ICH-guidlines for stability testing of drugs
ICH-guidlines for stability testing of drugsICH-guidlines for stability testing of drugs
ICH-guidlines for stability testing of drugs
 

More from Vivek Jain (8)

UNIT 3: Qulaity control tests
UNIT 3: Qulaity control tests UNIT 3: Qulaity control tests
UNIT 3: Qulaity control tests
 
Good Laboratory Practices AU. Vivek Jain
Good Laboratory Practices AU. Vivek JainGood Laboratory Practices AU. Vivek Jain
Good Laboratory Practices AU. Vivek Jain
 
Calibration
CalibrationCalibration
Calibration
 
Qualification
QualificationQualification
Qualification
 
Analytical Method Validation
Analytical Method Validation Analytical Method Validation
Analytical Method Validation
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek Jain
 
Quality Assurance and Quality Management Concepts
Quality Assurance and Quality Management ConceptsQuality Assurance and Quality Management Concepts
Quality Assurance and Quality Management Concepts
 
Nabl
NablNabl
Nabl
 

Recently uploaded

The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 

Recently uploaded (20)

Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 

Ich Guidelines Au. Vivek Jain

  • 1. As Per PCI Regulations /B. Parm. VI Sem./Pharmaceutical Quality Assurance UNIT-1 ICH Guideline Presented By: VIVEK JAIN M.Pharm. (Pharmaceutical Analysis) Associate Professor ADINA Institute Of Pharmaceutical Sciences, Sagar (M.P.) EMAIL:pharmamakers2010@gmail.com
  • 2.
  • 3. ICH (April 1990) • International Conference on Harmonisation (ICH) was created in april 1990 • The European Medicines Agency publishes scientific guidelines that are harmonised between Europe, Japan and the United States of America • ICH guidelines are provided for: Quality. Safety and Efficacy of medicines.
  • 4. MISSION Harmonisation for Better Health To make recommendations towards achieving greater harmonisation in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration and the maintenance of such registrations
  • 5. PURPOSE  To Harmonize of technical requirements for registration or marketing approval  To Ensure quality, safety, efficacy of medicines  To prevent unnecessary duplication of clinical trials on humans  To Minimize the use of animal testing without compromising safety and effectiveness  To promote public health
  • 6. history Need to harmonize, Because of the following reasons: 1. Industry becoming global 2. Duplicate test procedures  time consuming  expensive 3. Increase R &D costs 4. Meeting public demand • Initiation of ICH • 1980s Formulate European community • 1989s WHO conference on DRA, Paris • 1990s birth of ICH (created by all three Japan, USA & Europe) • Topic of harmonization divided into : safety, quality and efficacy
  • 7. ICH structure region Regulatory body Japan MHLW ( ministry of health, labour and welfare) Europe EU (European unions) US FDA
  • 9.
  • 10. Process of Harmonisation ICH harmonisation activities fall into 4 categories; 1.Formal ICH Procedure 2.Q&A Procedure 3.Revision Procedure 4,.Maintenance Procedure
  • 11.
  • 12. BRIEF OVERVIEW OF QSEM WITH SPECIAL EMPHASIS ON Q- SERIES GUIDELINES The ICH topics are divided into four categories •Q – QUALITY GUIDELINES •S – SAFETY GUIDELINES •E - EFFICACY GUIDELINES •M - MULTIDISCIPLINARY GUIDELINES •Carcinogenicity (carcinogen any substance that produce cancer) •Genotoxicity (genetic toxicity) •Reprotoxicity toxicity related to reproduction •ICH medical terminology (MedDRA) •Common Technical Document (CTD) •The development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).
  • 13. Q – QUALITY GUIDELINES Q 1 S Stability Q 2 A Analytical validation Q 3 I Impurities Q 4 P Pharmacopoeias Q 5 B Quality of Biotechnology Products Q 6 S Specifications Q 7 API Good Manufacturing Guide for Active Pharmaceutical Ingredients Q 8 PD Pharmaceutical Development Q 9 QRM Quality Risk Management Q 10 PQS Pharmaceutical Quality System Q 11 DMDS Development and Manufacture of Drug Substances (Chemical Entities Biotechnological/Biological Entities) Q 12 LCM Life Cycle Management
  • 14. Q – QUALITY GUIDELINES Q 1 A – Q 1 F Stability • Q1A – Stability Testing of New Drug Substances and Products • Q1 B – Stability Testing : Photo Stability Testing of New Drug Substances and Products • Q1C – Stability Testing for New Dosage Forms • Q1D – Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products • Q1E – Evaluation of Stability Data • Q1F – Stability Data Package for Registration Application in Climatic Zones III and IV Q2 (R1) – Validation of Analytical Procedures: Text and Methodology
  • 15. Q3A- Q3D Impurities • Q3A - Impurities in New Drug Substances • Q3B – Impurities in New Drug Products • Q3C– Impurities : Guideline for Residual Solvents • Q3D – Impurities : Guideline for Elemental Impurities • Q4 – Pharmacopoeias • Q4A – Pharmacopoeial Harmonisation • Q4B – Evaluation and Recommendation of Pharmacopoeial Text for use in the ICH Regions • • Q4B Annex 2(R1) – Test for Extractable Volume of Parenteral Preparation General Chapter • Q4B – Annex 3(R1) – Test for Particulate Contamination : Sub- Visibal Particales General Chapter
  • 16. • Q4B – Annex 4A(R1) – Microbiological Examination of Non- Sterile Products : Microbial Enumeration Tests General Chapter • Q4B – Annex 4B(R1) – Microbiological Examination of Non- Sterile Products : Test for Specified Micro-Organism General Chapter • Q4B – Annex 4C(R1) – Microbiological Examination of Non- Sterile Products : Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical use General Chapter • Q4B – Annex 5(R1) – Disintegration Test General Chapter
  • 17. • Q4B Annex 6 (R1) – Uniformity of Dosage Units General Chapter • Q4B Annex 7(R2) – Dissolution Test General Chapter • Q4B Annex 8(R1) – Stability Test General Chapter • Q4B Annex 9(R1) – Tablet Friability General Chapter • Q4B Annex 10(R1) – Polyacrylamide Gel Electrophoresis General Chapter • Q4B Annex 11 – Capillary Electrophoresis General Chapter • Q4B Annex 12 – Analytical Sieving General Chapter • Q4B Annex 13 – Bulk Density and Tapped Density of Powders General Chapter • Q4B Annex 14 – Bacterial Endotoxin Test General Chapter
  • 18. Q5A-Q5E Quality of Biotechnology Products • Q5A (R1) – Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin • Q5B – Quality of Biotechnology Products : • Q5C – Quality of Biotechnology Products :Quality of Biotechnological • Q5D – Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products • Q5E – Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process
  • 19. • Q6A-Q6B Specifications • Q6A – Specifications : Test Procedure and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances • Q6B – Specifications : Test Procedure and Acceptance Criteria for Biotechnological/Biological • Q7 – Good Manufacturing Guide for Active Pharmaceutical Ingredients • Q8(R2) – Pharmaceutical Development • Q9 – Quality Risk Management • Q10 – Pharmaceutical Quality System • Q11 – Development and Manufacture of Drug Substances (Chemical Entities Biotechnological/Biological Entities) • Q12 – Life Cycle Management
  • 20. S – SAFETY GUIDELINES • S1A - S1C Carcinogenicity Studies • S2 Genotoxicity Studies • S3A - S3B Toxicokinetics and Pharmacokinetics • S4 Toxicity Testing • S5 Reproductive Toxicology • S6 Biotechnological Products. • S7A - S7B Pharmacology Studies • S8 Immunotoxicology Studies • S9 Nonclinical evaluation for anticancer pharmaceuticals • S10 Photo safety evaluation • S11 Nonclinical paediatric safety
  • 21. E - EFFICACY GUIDELINES • E1 Clinical Safety For Drugs Used In Long-Term Treatment. • E2A - E2F Pharmacovigilance. • E3 Clinical Study Reports. • E4 Dose-Response Studies. • E5 Ethnic Factors. Code. • E6 Good Clinical Practice. • E7 Clinical Trials In Geriatric Population. • E8 General Considerations For Clinical Trials • E9 Statistical Principles For Clinical Trials • E10 Choice Of Control Group In Clinical Trials • E11 Clinical Trials In Paediatric Population • E12 Clinical Evaluation By Therapeutic Category • E14 Clinical Evaluation Of QT • E15 Definitions Of Pharmacogenetics • E16 Qualification Of Genomic Biomarkers • E17 Multiregional Clinical Trials • E18 Genomic Sampling • E19 Safety Data Collection
  • 22. M - MULTIDISCIPLINARY GUIDELINES • M1 MedDRA Terminology • M2 Electronic Standards • M3 Nonclinical Safety Studies • M4 Common Technical Document • M5 Data Elements and Standards for Drug Dictionaries • M6 Gene Therapy • M7 Genotoxic Impurities • M8 Electronic Common Technical Document (eCTD) • M9 Biopharmaceutics Classification System-based Biowaivers • M10 Bioanalytical Method Validation
  • 23. Stability guideline • General: • Definition: Stability of pharmaceutical product may be defined as the ability of pharmaceutical dosage form to maintain the physical, chemical, microbiological and therapeutics properties during the time of storage and usage by the patient • Purpose of stability testing is: To provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions.
  • 24. Stability protocol For Drug Substance • General • Stress testing • Selection of batches • Container and closure system • Specifications • Testing frequency • Storage conditions • Stability Commitment • Evaluation • Statements/Labeling
  • 25. Stress Testing • It is also known as force degradation study • Stress testing of the drug substance can help identify the likely degradation products, which can in turn help establish the degradation pathways and the intrinsic/natural stability of the molecule. • Stress testing is likely to be carried out on a single batch of the drug substance. • It should include the effect of temperatures, humidity (e.g., 75% RH or greater) where appropriate oxidation, and photolysis on the drug substance.
  • 26. Selection of Batches • At least three primary batches of the drug substance should be representative to quality of the material used for production scale. • Container Closure System • The stability studies should be conducted on the drug substance packaged in a container closure system that is the same as the packaging proposed for storage and distribution. • Specification • Specification, which is a list of tests, reference to analytical procedures, and proposed acceptance criteria, is addressed in ICH Q6A and Q6B.
  • 27. Testing Frequency frequency of testing should be sufficient to establish the stability profile of the drug substance. • For long-term studies, (For drug substances with a proposed re-test period) at least 12 months, the frequency of testing at the long term storage condition should normally be every 3 months over the first year, every 6 months over the second year, and annually thereafter through the proposed re-test period. • At the accelerated storage condition, a minimum of three time points, including the initial and final time points (e.g., 0, 3, and 6 months), from a 6-month study is recommended. • For intermediate studies: Min. 4 time points (0, 6, 9, 12 months) for a 12 months study
  • 28. Storage Conditions General case • . • Study Long term* Storage conditions 25°C ± 2°C 60% RH ± 5% RH Minimum time period 12 months Intermediate ** 30°C ± 2°C/65% RH ± 5% RH 6 months Accelerated 40°C ± 2°C/75% RH ± 5% RH 6 months
  • 29. . Drug substances intended for storage in a refrigerator Long term 5°C ± 3°C 12 months Accelerated 25°C±2°C 6 months
  • 30. Drug substances intended for storage in a freezer Long term - 20°C ± 5°C 12 months
  • 31. Stability Commitment • In case where data submitted for registration do not cover the proposed shelf life it is necessary to give commitment to continue the stability studies post approval in order to firmly establish the shelf life. • Where the submission includes long term stability data from three production batches covering the proposed shelf life, a post approval commitment is considered unnecessary.
  • 32. Evaluation • The purpose of the stability study is to establish re-test period for DS and shelf life for drug product for future batched based on evaluation of results obtained from chemical, physical, biological, microbiological tests • A systematic approach should be adopted in the presentation and evaluation of the stability information, which should include, as appropriate, results from the physical, chemical, biological, and microbiological tests, including particular attributes of the dosage form (for example, dissolution rate for solid oral dosage forms).
  • 33. Statements/Labeling • A storage statement should be established for the labeling in accordance with relevant national/regional requirements. • The statement should be based on the stability evaluation of the drug product. • There should be a direct link between the label storage statement and the demonstrated stability of the drug product. • An expiration date should be displayed on the container label.